In the next step, we examined the clinical and prognostic relevance of IL-6 and the percentage of PD-L1/PD-L2 positive monocytes/macrophages (MO/MA) in terms of their clinical and prognostic relevance in ovarian cancer patients. This evidence concerns the gene IL6 and ovarian carcinoma.